Concepts (276)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Injuries | 13 | 2024 | 129 | 4.680 |
Why?
|
| Brain Concussion | 6 | 2024 | 36 | 3.360 |
Why?
|
| Refugees | 2 | 2024 | 21 | 1.600 |
Why?
|
| Neurodegenerative Diseases | 3 | 2022 | 141 | 1.490 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2024 | 568 | 1.100 |
Why?
|
| Blast Injuries | 2 | 2023 | 6 | 0.960 |
Why?
|
| Glycomics | 2 | 2022 | 8 | 0.910 |
Why?
|
| Religion and Psychology | 1 | 2024 | 27 | 0.840 |
Why?
|
| Olfactory Receptor Neurons | 1 | 2024 | 30 | 0.830 |
Why?
|
| Receptors, Odorant | 1 | 2024 | 44 | 0.800 |
Why?
|
| Microglia | 3 | 2023 | 208 | 0.790 |
Why?
|
| Proteomics | 11 | 2023 | 378 | 0.780 |
Why?
|
| Tinnitus | 1 | 2022 | 4 | 0.750 |
Why?
|
| Craniocerebral Trauma | 1 | 2022 | 22 | 0.750 |
Why?
|
| Humans | 51 | 2024 | 43102 | 0.730 |
Why?
|
| Epilepsy | 1 | 2022 | 59 | 0.710 |
Why?
|
| Nervous System Diseases | 1 | 2022 | 77 | 0.710 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 32 | 0.710 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 136 | 0.620 |
Why?
|
| Methamphetamine | 1 | 2021 | 166 | 0.610 |
Why?
|
| Animals | 23 | 2024 | 16992 | 0.610 |
Why?
|
| Foramen Magnum | 3 | 2022 | 3 | 0.570 |
Why?
|
| Rats | 12 | 2024 | 3735 | 0.570 |
Why?
|
| Vietnam | 3 | 2022 | 62 | 0.560 |
Why?
|
| Proteome | 3 | 2023 | 152 | 0.510 |
Why?
|
| Depression | 1 | 2024 | 863 | 0.500 |
Why?
|
| Anxiety | 1 | 2024 | 874 | 0.490 |
Why?
|
| Brain | 6 | 2023 | 1472 | 0.460 |
Why?
|
| Lebanon | 3 | 2024 | 21 | 0.450 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2024 | 57 | 0.450 |
Why?
|
| Syria | 2 | 2024 | 5 | 0.410 |
Why?
|
| Narcolepsy | 2 | 2023 | 2 | 0.410 |
Why?
|
| Mice, Inbred C57BL | 4 | 2022 | 1869 | 0.400 |
Why?
|
| Tauopathies | 2 | 2024 | 22 | 0.400 |
Why?
|
| Glial Fibrillary Acidic Protein | 5 | 2024 | 75 | 0.400 |
Why?
|
| MicroRNAs | 3 | 2024 | 518 | 0.390 |
Why?
|
| Astrocytes | 3 | 2023 | 244 | 0.380 |
Why?
|
| Vietnam Conflict | 2 | 2022 | 6 | 0.380 |
Why?
|
| Morphine | 2 | 2024 | 69 | 0.370 |
Why?
|
| Gene Expression Profiling | 4 | 2024 | 704 | 0.370 |
Why?
|
| Analgesics, Opioid | 3 | 2024 | 252 | 0.360 |
Why?
|
| Glioblastoma | 2 | 2023 | 74 | 0.350 |
Why?
|
| Mice | 7 | 2023 | 6644 | 0.330 |
Why?
|
| Alzheimer Disease | 3 | 2024 | 1001 | 0.320 |
Why?
|
| Antioxidants | 3 | 2023 | 443 | 0.320 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 1596 | 0.300 |
Why?
|
| Inflammation | 3 | 2023 | 758 | 0.290 |
Why?
|
| Male | 14 | 2024 | 23409 | 0.280 |
Why?
|
| Colorectal Neoplasms | 2 | 2023 | 512 | 0.250 |
Why?
|
| Aptamers, Nucleotide | 2 | 2024 | 51 | 0.250 |
Why?
|
| Glycopeptides | 2 | 2023 | 14 | 0.250 |
Why?
|
| Hypertension | 2 | 2024 | 835 | 0.250 |
Why?
|
| tau Proteins | 2 | 2024 | 186 | 0.230 |
Why?
|
| Reactive Oxygen Species | 3 | 2023 | 532 | 0.220 |
Why?
|
| Point-of-Care Systems | 2 | 2022 | 35 | 0.220 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 30 | 0.210 |
Why?
|
| Maze Learning | 2 | 2021 | 113 | 0.210 |
Why?
|
| Hematologic Tests | 1 | 2024 | 7 | 0.210 |
Why?
|
| Drug Tolerance | 1 | 2024 | 26 | 0.210 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2024 | 22 | 0.210 |
Why?
|
| Unemployment | 1 | 2024 | 29 | 0.210 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2023 | 5 | 0.210 |
Why?
|
| Adipokines | 1 | 2023 | 28 | 0.200 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2024 | 51 | 0.200 |
Why?
|
| Neurosciences | 1 | 2024 | 34 | 0.200 |
Why?
|
| Weight Loss | 1 | 2024 | 137 | 0.200 |
Why?
|
| Status Epilepticus | 1 | 2023 | 15 | 0.200 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2023 | 44 | 0.200 |
Why?
|
| Satureja | 1 | 2023 | 1 | 0.200 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 1019 | 0.200 |
Why?
|
| Leptin | 1 | 2024 | 118 | 0.200 |
Why?
|
| Plague | 1 | 2023 | 25 | 0.200 |
Why?
|
| Brain Edema | 1 | 2023 | 64 | 0.200 |
Why?
|
| Oils, Volatile | 1 | 2023 | 13 | 0.200 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2023 | 34 | 0.200 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2022 | 10 | 0.190 |
Why?
|
| Trauma Centers | 1 | 2023 | 92 | 0.190 |
Why?
|
| Neurons | 4 | 2024 | 1263 | 0.190 |
Why?
|
| Bupropion | 1 | 2022 | 13 | 0.190 |
Why?
|
| Fluorouracil | 1 | 2023 | 47 | 0.190 |
Why?
|
| Encephalitis | 1 | 2023 | 43 | 0.190 |
Why?
|
| Unconsciousness | 1 | 2022 | 4 | 0.190 |
Why?
|
| Female | 10 | 2024 | 24698 | 0.190 |
Why?
|
| Carbohydrates | 1 | 2022 | 32 | 0.190 |
Why?
|
| Gasoline | 1 | 2022 | 3 | 0.180 |
Why?
|
| Ubiquinone | 1 | 2022 | 23 | 0.180 |
Why?
|
| RNA | 1 | 2024 | 266 | 0.180 |
Why?
|
| Organophosphorus Compounds | 1 | 2022 | 37 | 0.180 |
Why?
|
| Spermatic Cord Torsion | 1 | 2021 | 2 | 0.180 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2022 | 70 | 0.180 |
Why?
|
| Schizophrenia | 1 | 2022 | 93 | 0.180 |
Why?
|
| Calcium Channels, T-Type | 1 | 2021 | 4 | 0.180 |
Why?
|
| Furin | 1 | 2021 | 6 | 0.180 |
Why?
|
| Meningeal Neoplasms | 1 | 2021 | 5 | 0.180 |
Why?
|
| Meningioma | 1 | 2021 | 7 | 0.180 |
Why?
|
| Annexin A1 | 1 | 2021 | 4 | 0.180 |
Why?
|
| Trypsin | 1 | 2021 | 40 | 0.180 |
Why?
|
| Transients and Migrants | 1 | 2021 | 42 | 0.180 |
Why?
|
| Nonlinear Dynamics | 1 | 2021 | 35 | 0.180 |
Why?
|
| Atherosclerosis | 1 | 2023 | 169 | 0.170 |
Why?
|
| Databases, Nucleic Acid | 1 | 2021 | 30 | 0.170 |
Why?
|
| Serum Amyloid P-Component | 1 | 2021 | 21 | 0.170 |
Why?
|
| Hyperalgesia | 1 | 2021 | 24 | 0.170 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2022 | 77 | 0.170 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 48 | 0.170 |
Why?
|
| Nanotubes, Carbon | 1 | 2022 | 87 | 0.170 |
Why?
|
| Metabolome | 1 | 2021 | 51 | 0.170 |
Why?
|
| Hemorrhage | 1 | 2021 | 55 | 0.170 |
Why?
|
| Flavonoids | 1 | 2022 | 100 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 291 | 0.170 |
Why?
|
| Marijuana Abuse | 1 | 2022 | 100 | 0.170 |
Why?
|
| Aspirin | 1 | 2022 | 89 | 0.170 |
Why?
|
| Models, Psychological | 1 | 2021 | 140 | 0.170 |
Why?
|
| Gene Frequency | 1 | 2021 | 206 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 101 | 0.170 |
Why?
|
| Nitrates | 1 | 2021 | 63 | 0.170 |
Why?
|
| Young Adult | 4 | 2024 | 5080 | 0.170 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 166 | 0.160 |
Why?
|
| Sex Factors | 1 | 2024 | 1028 | 0.160 |
Why?
|
| Models, Neurological | 1 | 2021 | 136 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 167 | 0.160 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 79 | 0.160 |
Why?
|
| Alleles | 1 | 2021 | 352 | 0.160 |
Why?
|
| Dietary Supplements | 1 | 2022 | 213 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2021 | 144 | 0.160 |
Why?
|
| Flow Cytometry | 1 | 2021 | 411 | 0.160 |
Why?
|
| Insulin Resistance | 1 | 2022 | 201 | 0.160 |
Why?
|
| Calcium | 1 | 2023 | 491 | 0.160 |
Why?
|
| Disasters | 1 | 2021 | 79 | 0.160 |
Why?
|
| Obesity | 3 | 2023 | 1151 | 0.160 |
Why?
|
| Opioid-Related Disorders | 1 | 2023 | 195 | 0.160 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 140 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 228 | 0.150 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 187 | 0.150 |
Why?
|
| Software | 1 | 2021 | 236 | 0.150 |
Why?
|
| Prevalence | 1 | 2024 | 1612 | 0.150 |
Why?
|
| RNA, Messenger | 1 | 2024 | 1271 | 0.150 |
Why?
|
| Oxidative Stress | 2 | 2023 | 1003 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2023 | 415 | 0.150 |
Why?
|
| Pain | 1 | 2022 | 290 | 0.150 |
Why?
|
| Signal Transduction | 3 | 2023 | 2157 | 0.150 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 1081 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3156 | 0.140 |
Why?
|
| Child | 5 | 2024 | 3443 | 0.140 |
Why?
|
| Rats, Wistar | 3 | 2024 | 283 | 0.140 |
Why?
|
| Membrane Proteins | 1 | 2021 | 561 | 0.130 |
Why?
|
| Cytokines | 1 | 2021 | 678 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 734 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2022 | 460 | 0.130 |
Why?
|
| Middle Aged | 4 | 2024 | 12222 | 0.120 |
Why?
|
| Adult | 4 | 2024 | 13872 | 0.110 |
Why?
|
| Risk Factors | 1 | 2023 | 3994 | 0.110 |
Why?
|
| Antibodies | 2 | 2024 | 144 | 0.100 |
Why?
|
| Peptide Hydrolases | 2 | 2023 | 44 | 0.100 |
Why?
|
| Explosions | 2 | 2022 | 6 | 0.090 |
Why?
|
| Chromatography, Liquid | 2 | 2023 | 182 | 0.090 |
Why?
|
| Pain Measurement | 2 | 2024 | 183 | 0.090 |
Why?
|
| Adipose Tissue | 2 | 2023 | 182 | 0.090 |
Why?
|
| Drug Discovery | 2 | 2023 | 108 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2024 | 986 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2023 | 241 | 0.080 |
Why?
|
| Apoptosis | 3 | 2023 | 1568 | 0.080 |
Why?
|
| Mass Spectrometry | 2 | 2021 | 280 | 0.080 |
Why?
|
| Prognosis | 2 | 2023 | 861 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2024 | 1759 | 0.080 |
Why?
|
| Peptides | 2 | 2023 | 372 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 934 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1600 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2024 | 2544 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 2676 | 0.060 |
Why?
|
| Diffuse Axonal Injury | 1 | 2024 | 1 | 0.050 |
Why?
|
| Glasgow Outcome Scale | 1 | 2024 | 5 | 0.050 |
Why?
|
| Okadaic Acid | 1 | 2024 | 16 | 0.050 |
Why?
|
| Naloxone | 1 | 2024 | 56 | 0.050 |
Why?
|
| SELEX Aptamer Technique | 1 | 2024 | 16 | 0.050 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 78 | 0.050 |
Why?
|
| DNA Polymerase I | 1 | 2023 | 4 | 0.050 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2023 | 6 | 0.050 |
Why?
|
| Serum | 1 | 2023 | 17 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 12 | 0.050 |
Why?
|
| Adamantane | 1 | 2023 | 10 | 0.050 |
Why?
|
| Cinnamates | 1 | 2023 | 7 | 0.050 |
Why?
|
| Arvicolinae | 1 | 2023 | 20 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2023 | 19 | 0.050 |
Why?
|
| Basement Membrane | 1 | 2023 | 26 | 0.050 |
Why?
|
| Cameroon | 1 | 2023 | 35 | 0.050 |
Why?
|
| Diazepam | 1 | 2023 | 10 | 0.050 |
Why?
|
| ROC Curve | 1 | 2024 | 159 | 0.050 |
Why?
|
| Excipients | 1 | 2023 | 25 | 0.050 |
Why?
|
| Bicycling | 1 | 2023 | 18 | 0.050 |
Why?
|
| Glycosylation | 1 | 2023 | 113 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2024 | 100 | 0.050 |
Why?
|
| Critical Care | 1 | 2023 | 49 | 0.050 |
Why?
|
| 3' Untranslated Regions | 1 | 2023 | 82 | 0.050 |
Why?
|
| Carbazoles | 1 | 2023 | 49 | 0.050 |
Why?
|
| Myelin Sheath | 1 | 2023 | 46 | 0.050 |
Why?
|
| Neurogenesis | 1 | 2023 | 63 | 0.050 |
Why?
|
| Furans | 1 | 2023 | 40 | 0.050 |
Why?
|
| Rare Diseases | 1 | 2022 | 17 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 51 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2023 | 125 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 17 | 0.050 |
Why?
|
| Caspase 6 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Iran | 1 | 2023 | 202 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2022 | 20 | 0.050 |
Why?
|
| Ligands | 1 | 2024 | 388 | 0.050 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 74 | 0.050 |
Why?
|
| Naltrexone | 1 | 2022 | 34 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2022 | 72 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2023 | 127 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2023 | 95 | 0.050 |
Why?
|
| Calpain | 1 | 2022 | 35 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2023 | 227 | 0.050 |
Why?
|
| Interleukin-2 | 1 | 2022 | 91 | 0.050 |
Why?
|
| Extracellular Matrix | 1 | 2023 | 131 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2021 | 9 | 0.050 |
Why?
|
| Nanomedicine | 1 | 2022 | 52 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2022 | 44 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 183 | 0.040 |
Why?
|
| Scrotum | 1 | 2021 | 4 | 0.040 |
Why?
|
| Posterior Horn Cells | 1 | 2021 | 3 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 259 | 0.040 |
Why?
|
| Mibefradil | 1 | 2021 | 2 | 0.040 |
Why?
|
| Europe | 1 | 2021 | 115 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2022 | 165 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2023 | 173 | 0.040 |
Why?
|
| Amiloride | 1 | 2021 | 19 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2021 | 7 | 0.040 |
Why?
|
| Injections, Intraperitoneal | 1 | 2021 | 60 | 0.040 |
Why?
|
| Biological Assay | 1 | 2021 | 63 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2021 | 34 | 0.040 |
Why?
|
| Lymph Node Excision | 1 | 2021 | 25 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2023 | 457 | 0.040 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 287 | 0.040 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2021 | 102 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2023 | 220 | 0.040 |
Why?
|
| Sweat | 1 | 2021 | 17 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 81 | 0.040 |
Why?
|
| Carcinogens | 1 | 2022 | 126 | 0.040 |
Why?
|
| Receptors, Opioid, mu | 1 | 2021 | 52 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2023 | 263 | 0.040 |
Why?
|
| Adolescent | 2 | 2023 | 6081 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2021 | 135 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 972 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2021 | 72 | 0.040 |
Why?
|
| Biopsy | 1 | 2021 | 177 | 0.040 |
Why?
|
| Metabolomics | 1 | 2021 | 95 | 0.040 |
Why?
|
| Mammals | 1 | 2021 | 112 | 0.040 |
Why?
|
| Dopamine | 1 | 2022 | 275 | 0.040 |
Why?
|
| Protein Conformation | 1 | 2021 | 416 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 1175 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 368 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2024 | 403 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2021 | 139 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2023 | 358 | 0.040 |
Why?
|
| Aged | 2 | 2024 | 8214 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2024 | 925 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 307 | 0.040 |
Why?
|
| Hippocampus | 1 | 2023 | 594 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 760 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 259 | 0.040 |
Why?
|
| Research Design | 1 | 2021 | 385 | 0.040 |
Why?
|
| Mitochondria | 1 | 2023 | 523 | 0.040 |
Why?
|
| Computational Biology | 1 | 2021 | 327 | 0.040 |
Why?
|
| Lung | 1 | 2022 | 492 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2021 | 1180 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1124 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2023 | 735 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 1604 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1154 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2023 | 1455 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 749 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 968 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2022 | 2853 | 0.030 |
Why?
|
| United States | 1 | 2021 | 5205 | 0.020 |
Why?
|
| Neoplasms | 1 | 2022 | 1377 | 0.020 |
Why?
|